DK0806941T3 - Liposomalt antibakterielt præparat med lav fasthed - Google Patents

Liposomalt antibakterielt præparat med lav fasthed

Info

Publication number
DK0806941T3
DK0806941T3 DK95940928T DK95940928T DK0806941T3 DK 0806941 T3 DK0806941 T3 DK 0806941T3 DK 95940928 T DK95940928 T DK 95940928T DK 95940928 T DK95940928 T DK 95940928T DK 0806941 T3 DK0806941 T3 DK 0806941T3
Authority
DK
Denmark
Prior art keywords
liposomal
antibacterial preparation
agent
low firm
firm
Prior art date
Application number
DK95940928T
Other languages
Danish (da)
English (en)
Inventor
Jacqueline Lagace
Christian Beaulac
Sebastien Clement-Major
Original Assignee
Univ Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23430112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0806941(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Montreal filed Critical Univ Montreal
Application granted granted Critical
Publication of DK0806941T3 publication Critical patent/DK0806941T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
DK95940928T 1994-12-23 1995-12-22 Liposomalt antibakterielt præparat med lav fasthed DK0806941T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/363,416 US5662929A (en) 1994-12-23 1994-12-23 Therapeutic liposomal formulation
PCT/CA1995/000713 WO1996019972A1 (en) 1994-12-23 1995-12-22 Low rigidity liposomal antibacterial composition

Publications (1)

Publication Number Publication Date
DK0806941T3 true DK0806941T3 (da) 2003-07-21

Family

ID=23430112

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95940928T DK0806941T3 (da) 1994-12-23 1995-12-22 Liposomalt antibakterielt præparat med lav fasthed

Country Status (14)

Country Link
US (1) US5662929A (es)
EP (1) EP0806941B1 (es)
JP (1) JP4523078B2 (es)
KR (1) KR100438657B1 (es)
AT (1) ATE235229T1 (es)
AU (1) AU702463B2 (es)
BR (2) BRPI9510423B8 (es)
CA (1) CA2206296C (es)
DE (1) DE69530124T2 (es)
DK (1) DK0806941T3 (es)
ES (1) ES2196092T3 (es)
NZ (1) NZ297364A (es)
PT (1) PT806941E (es)
WO (1) WO1996019972A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6443949B2 (en) * 1997-03-13 2002-09-03 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
US6511477B2 (en) 1997-03-13 2003-01-28 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
US6054133A (en) * 1997-07-10 2000-04-25 The Regents Of The University Of California Anti-microbial targeting for intracellular pathogens
US6613352B2 (en) * 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
US6365138B1 (en) * 2000-04-07 2002-04-02 The Regents Of The University Of California Compositions for metabolic protection and repair of lips
DE60135743D1 (de) * 2000-06-16 2008-10-23 Sloan Kettering Inst Cancer Liposomale einkapselung von alphastrahlern, und deren verwendung
ES2406405T3 (es) 2000-12-27 2013-06-06 Gilead Sciences, Inc. Aztreonam inhalable sin arginina para tratamiento y prevención de infecciones bacterianas pulmonares
US7214364B2 (en) 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
WO2003075889A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
DE10214983A1 (de) * 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
DK2363114T3 (da) * 2002-10-29 2015-06-22 Insmed Inc Opretholdt afgivelse af anti-infektionsmidler
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
DE10255285A1 (de) * 2002-11-26 2004-06-03 Mcs Micro Carrier Systems Gmbh Selbst formende Phospholipid-Gele
ATE350024T1 (de) * 2003-10-15 2007-01-15 Pari Gmbh Flüssige zubereitung enthaltend tobramycin
WO2005044226A2 (en) * 2003-11-04 2005-05-19 Nectar Therapeutics Lipid formulations for spontaneous drug encapsulation
PT1962805T (pt) 2005-12-08 2016-10-05 Insmed Inc Composições de anti-infeciosos baseadas em lípidos para tratamento de infeções pulmonares
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
DE102009031274A1 (de) 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomen zur pulmonalen Applikation
EP2731590B1 (en) 2011-07-13 2018-05-23 The Foundry, LLC Methods and apparatus for delivering a therapeutic agent to nasopharyngeal mucosa targets
JP6402097B2 (ja) 2012-05-21 2018-10-10 インスメッド インコーポレイテッド 肺感染症を処置するためのシステム
MX2015006681A (es) 2012-11-29 2016-04-06 Insmed Inc Formulaciones de vancomicina estabilizadas.
WO2015175939A1 (en) 2014-05-15 2015-11-19 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
CN106999419A (zh) * 2014-08-04 2017-08-01 佐尼奥尼制药股份有限公司 远程装载略微水溶性药物至脂质膜泡
ES2574615B1 (es) * 2014-12-19 2017-07-24 Biopraxis Research Aie Nanopartícula lipídica de tobramicina
EP3655028A4 (en) * 2017-10-02 2021-06-09 Aridis Pharmaceuticals, Inc. COMPOSITIONS AND METHODS AGAINST P. AERUGINOSA INFECTIONS
EP3773505A4 (en) 2018-03-30 2021-12-22 Insmed Incorporated PROCESS FOR THE CONTINUOUS MANUFACTURING OF LIPOSOMAL MEDICINAL PRODUCTS
CN117017999A (zh) * 2023-09-20 2023-11-10 四川大学 一种夫西地酸磷脂复合物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4981692A (en) * 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
US4753788A (en) * 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
US4952405A (en) * 1988-10-20 1990-08-28 Liposome Technology, Inc. Method of treating M. avium infection
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
PT100486B (pt) * 1992-05-14 1999-07-30 Ineti Inst Nac Engenh E Tecnol Aminoglucosidos lipossomais com altas eficacia de encapsulacao e actividade terapeutica, nomeadamente a netilmicina, e processo para a sua preparcao
WO1994012155A1 (en) * 1992-12-02 1994-06-09 Vestar, Inc. Antibiotic formulation and process

Also Published As

Publication number Publication date
CA2206296C (en) 2007-05-22
CA2206296A1 (en) 1996-07-04
KR100438657B1 (ko) 2004-08-18
US5662929A (en) 1997-09-02
JPH10511363A (ja) 1998-11-04
BR9510423A (pt) 2003-01-07
AU702463B2 (en) 1999-02-25
BRPI9510423B8 (pt) 2019-11-05
MX9704679A (es) 1998-07-31
AU4251096A (en) 1996-07-19
ES2196092T3 (es) 2003-12-16
EP0806941B1 (en) 2003-03-26
ATE235229T1 (de) 2003-04-15
KR980700062A (ko) 1998-03-30
NZ297364A (en) 2000-01-28
DE69530124T2 (de) 2004-02-05
DE69530124D1 (de) 2003-04-30
PT806941E (pt) 2003-08-29
WO1996019972A1 (en) 1996-07-04
JP4523078B2 (ja) 2010-08-11
EP0806941A1 (en) 1997-11-19

Similar Documents

Publication Publication Date Title
DK0806941T3 (da) Liposomalt antibakterielt præparat med lav fasthed
MXPA02002895A (es) Tratamiento topico de infecciones por estreptococcus.
ES2188652T3 (es) Sistema de direccionado de farmacos, metodos de fabricacion y uso del mismo.
MY115351A (en) Pharmaceutical formulations
NO954996D0 (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
MY125356A (en) Moxifloxacin/sodium chloride formulation
ES2074698T3 (es) Composicion oral para el tratamiento de enfermedades intestinales inflamatorias.
BRPI9915480B8 (pt) azalídeos de 13 membros, composições farmacêuticas compreendendo os mesmos, método para sua preparação bem como seus usos.
IL151628A0 (en) Combination therapies with vascular damaging activity
DK98089D0 (da) Medikament-lipid-systemer med lav toxicitet
EE9900428A (et) Köhavastased ravimkoostised
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
WO2000012049A3 (en) A method for the treatment of staphylococcal disease
KR950026524A (ko) 피부질환 치료용 의약조성물
NZ510153A (en) Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals
ATE108651T1 (de) Aktives mittel: lipid-komplex mit hohem verhältnis.
AU5643299A (en) Humic acid and its use in the treatment of various conditions
CA2091134A1 (en) Therapeutic agent for threatened abortion
ES8607728A1 (es) Procedimiento de preparacion de una nueva composicion anti- biotica sinergetica, de uso veterinario
GR3004655T3 (es)
DE69941459D1 (de) Verfahren zur herstellung von essbaren zusammenstellungen mit antibakteriellen wirkstoffen
CA2120917A1 (en) External preparation for treating hemorrhoidal diseases
MY101079A (en) Pharmaceutical formulation for the treatment of bacterial infections.
Olay et al. Experimental Staphylococcus aureus osteomyelitis treated with fosfomycin and cephazolin: Single and combined therapy.